Chromogranin A (GEP-NET surveillance, MEN1)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-CHROMOGRANIN-A-NET |
|---|---|
| Type | Biomarker |
| Aliases | CHGACgAChromogranin AХромогранін A (нагляд GEP-NET, MEN1) |
| Status | reviewed 2026-05-18 | pending_clinical_signoff |
| Diseases | DIS-PNET |
| Sources | SRC-ENDOCRINE-SOCIETY-MEN-2023 SRC-NCCN-NET-2025 |
Biomarker Facts
| Biomarker type | serum_marker |
|---|---|
| Measurement | MethodSerum immunoassay (RIA or ELISA); assay-dependent reference ranges Unitsng/mL Typical range
|
| Related biomarkers | None declared |
Notes
Granin-family secretory protein, ubiquitously expressed in neuroendocrine cells. Used as a non-specific biomarker for GEP-NET (gastroenteropancreatic neuroendocrine tumors), MEN1-associated NETs (pancreatic, foregut), and pheochromocytoma (but plasma metanephrines preferred for pheo). NCCN recommends CgA as ADJUNCT, not standalone — annual surveillance in MEN1 carriers (pancreatic NET screening) typically combined with cross-sectional imaging (MRI or EUS) and gastrin/insulin/glucagon/VIP/PP panels per symptoms. Major confounders driving false-positive elevations: proton-pump inhibitor use (most common cause of elevation in clinical practice), atrophic gastritis, renal impairment, heart failure, chronic hepatitis, IBD. Less sensitive than gut-hormone panel for functional NETs. Limited utility for non-functioning small NETs. STUB pending two-Co-Lead signoff.
Used By
Actionability
BMA-CHROMOGRANIN-A-NET-MEN1-SURVEILLANCE- Chromogranin A (CgA) is a granin-family secretory protein expressed ubiquitously in neuro...